Evidence Table. Study Type: Randomized controlled trial. Study Aim: To evaluate the safety and efficacy of the X-Stop interspinous implant.

Similar documents
ProDisc-L Total Disc Replacement. IDE Clinical Study

BSD Journal of Spinal Disorders and Techniques Publish Ahead of Print DOI: /BSD.0b013e31827b671f

Lumbar spinal stenosis is narrowing of the spinal canal that results in compression of the cauda

Am I eligible for the TOPS study? Possibly, if you suffer from one or more of the following conditions:

QF-78. S. Tanaka 1, T.Yokoyama 1, K.Takeuchi 1, K.Wada 2, T. Tanaka 2, S.Abrakawa 2, G.Kumagai 2, T.Asari 2, A.Ono 2, Y.

ProDisc-L Total Disc Replacement. IDE Clinical Study.

Current Spine Procedures

Jessica Jameson MD Post Falls, ID

Comprehension of the common spine disorder.

The ABC s of LUMBAR SPINE DISEASE

FDA Executive Summary

Clinical Policy Title: Interspinous dynamic stabilization devices

LUMBAR SPINAL STENOSIS

Chapter 35. Clinical Results of IDE Trial of X- Stop Interspinous Systems Lumbar Spinal Stenosis Treatment 2

Scoliosis and interspinous decompression with the X-STOP: prospective minimum 1-year outcomes in lumbar spinal stenosis

SpineFAQs. Lumbar Spondylolisthesis

Corporate Medical Policy

Get back to: my life. Non-fusion treatment for lumbar spinal stenosis

PARADIGM SPINE. Interlaminar Technology. Interlaminar Implant

Lumbar Spinal Stenosis

Interlaminar Decompression & Stabilization. Reginald Davis, M.D., FAANS, FACS Director of Clinical Research

Link to author version on UHI Research Database

The ABC s of LUMBAR SPINE DISEASE

5/19/2017. Interspinous Process Fixation with the Minuteman G3. What is the Minuteman G3. How Does it Work?

Plano, TX, 8 Senta Clinic, San Diego, CA

Original Policy Date 12/2013

DEGENERATIVE SPONDYLOLISTHESIS

Interspinous and Interlaminar Stabilization/Distraction Devices (Spacers)

Supplementary Appendix

Subject: Interspinous Decompression Devices for Spinal Stenosis (X Stop, Coflex) Guidance Number: MCG-222 Revision Date(s):

Life can cause spinal stenosis. Take yours back with Superion.

Objectives. Comprehension of the common spine disorder

Spine Pain Management Program

coflex Interlaminar Technology

Spine Pain Management Program

Corporate Medical Policy

Aperius interspinous implant versus open surgical decompression in lumbar spinal stenosis

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

LUMBAR SPINAL STENOSIS

PROF. EPIMENIO RAMUNDO ORLANDO

Original Article Management of Single Level Lumbar Degenerative Spondylolisthesis: Decompression Alone or Decompression and Fusion

Anesthesiology Pain Medicine

Non-Operative Management of Low Back Pain in the Elderly

University of Jordan. Professor Freih Abuhassan -

Spine Tango annual report 2012

Spine Pain Management Program

Kyphon Investor & Analyst Meeting. May 17, 2007

Common Thoraco- Lumbar Problems in the Mature Athlete

Degenerative Disease of the Spine

MEDICAL POLICY MEDICAL POLICY DETAILS POLICY STATEMENT. Page: 1 of 5

High failure rate of the interspinous distraction device (X-Stop) for the treatment of lumbar spinal stenosis caused by degenerative spondylolisthesis

Lumbar Spinal Fusion Corporate Medical Policy

Peggers Super Summaries: The Aging Spine

Spine Pain Management Program

Cox Technic Case Report #169 published at (sent 5/9/17) 1

PARADIGM SPINE. Patient Information. Treatment of a Narrow Lumbar Spinal Canal

THORACO-LUMBAR STENOSIS

Protocol. Interspinous and Interlaminar Stabilization/Distraction Devices (Spacers)

Interspinous and Interlaminar Stabilization / Distraction Devices (Spacers)

5/27/2016. Stand-Alone Lumbar Lateral Interbody Fusion (LLIF) vs. Supplemental Fixation. Disclosures. LLIF Approach

Retrospective Analysis of coflex : Long-term Cohort in 240 Patients

Epidemiology of Low back pain

The imaging features of spondylolisthesis : what the clinician needs to know

Subaxial Cervical Spine Trauma. Introduction. Anatomic Considerations 7/23/2018

Patient Selection and Lumbar Operative Interventions

A New Approach to Quantify Functional Improvements Following X-Stop Spacer Procedure: A Case Report

Comparison of Clinical Outcomes Following Minimally Invasive Lateral Interbody Fusion Stratified by Preoperative Diagnosis

DEGENERATIVE SPINAL DISEASE PRABIN SHRESTHA ANISH M SINGH B&B HOSPITAL

Osteoarthrosis, unspecified whether generalized or localized, lower leg. Osteoarthrosis, localized, not specified whether primary or secondary, pelvic

Lumbar spinal canal stenosis Degenerative diseases F 08

Patient Information MIS LLIF. Lateral Lumbar Interbody Fusion Using Minimally Invasive Surgical Techniques

Populations Interventions Comparators Outcomes Individuals: With spinal stenosis and up to grade I spondylolisthesis

Related Policies None

R/F. Use of Tomosynthesis at the Aizawa Hospital. 1. Introduction. 2. Use of Tomosynthesis at the Aizawa Hospital

Fracture REduction Evaluation (FREE) Study

Lumbar Laminotomy DEFINING APPROPRIATE COVERAGE POSITIONS NASS COVERAGE POLICY RECOMMENDATIONS TASKFORCE

3D titanium interbody fusion cages sharx. White Paper

2016 OPAM Mid-Year Educational Conference, sponsored by AOCOPM Thursday, March 10, 2016 C-1

Cover Page. The handle holds various files of this Leiden University dissertation.

ILIF Interlaminar Lumbar Instrumented Fusion. Anton Thompkins, M.D.

A Structural Service Plan: Towards Better and Safer Spine Surgeries. Department of Orthopaedics & Traumatology Tuen Mun Hospital

Image-Guided Minimally Invasive Lumbar Decompression (IG-MLD) for Spinal Stenosis

The Incidence Of An Epidural Hematoma Following Cervical Spine Surgery

Stage Operation for Unstable Lumbar Spine Fracture- Dislocation with Incomplete Paraplegia: A Case Series

Interventional Pain Management

Fractures of the Thoracic and Lumbar Spine

Lumbar Spinal Stenosis

Prodisc-L. Retrospective Clinical Study: 7 to 11 Year Follow-up.

Overview Anatomy of the spinal canal What is spinal stenosis? > 1

Original Date: October 2015 LUMBAR SPINAL FUSION FOR

A Patient s Guide to Lumbar Spinal Stenosis

Common fracture & dislocation of the cervical spine. Theerachai Apivatthakakul Department of Orthopaedic Chiangmai University

ESCOME Pre-Course Outline (v1.09)

Life can cause spinal stenosis. Take yours back with Superion.

HIGH LEVEL - Science

Departement of Neurosurgery A.O.R.N A. Cardarelli- Naples.

Posterior lumbar interbody fusion versus intertransverse fusion in the treatment of lumbar spondylolisthesis

The clinical features and surgical treatment of degenerative lumbar scoliosis: A review of 112 patientsos4_

CERVICAL SPONDYLOSIS & CERVICAL DISC DISEASE

Transcription:

Evidence Table Clinical Area: Reference: Spinal decompression device for lumbar spinal stenosis Zucherman JF et al. A prospective randomized multi-center study for the treatment of lumbar spinal stenosis with the X-Stop interspinous implant: 1-year results. Eur Spine J 2004; 12:22-31. Zucherman JF et al. A multicenter, prospective, randomized trial evaluating the X-Stop interspinous process decompression system for the treatment of neurogenic intermittent claudication: 2-year followup results. Spine 2005; 30: 1351-1358. Study Type: Randomized controlled trial. Study Aim: To evaluate the safety and efficacy of the X-Stop interspinous implant. Outcomes Primary: SF-36, Zurich Claudication Questionnaire (ZCQ) Secondary: Radiography. Design Number of subjects: N=200 randomized, n=191 treated (n=100 X-Stop, n=91 non-operative group). Description of study population: Conducted at 9 centers. X-Stop group: Mean age=69.9 years, 57 males/43 females, mean duration of pain=3.5 years; 76% 1 level, 24% 2 levels: Preoperative group: Mean age=68.6 years, 52 males/48 females, mean duration of pain=4.7 years; 80% 1 level, 20% 2 levels. Inclusion criteria: 50 years old; leg, buttock or groin pain with or without back pain that is relieved during flexion. Required that patients be able to sit for 50 minutes without pain, walk 50 feet and have completed 6 months of non-operative therapy. Also required stenosis confirmed by CT or MRI scans at 1 or 2 levels. Exclusion criteria: Fixed motor deficit, cauda equina syndrome, significant lumbar instability, previous lumbar surgery, significant peripheral neuropathy, Cobb angle >25 o, spondylolisthesis >grade 1.0 (scale of 1-4), sustained pathologic fractures, severe osteoporosis of the vertebra or hips, obesity, active infection, systemic disease, Paget s disease, metastasis to the vertebrae, steroid use for >1 month within 12 months of study participation. Intervention: Randomized to either the X-Stop group or a non-operative group. The nonoperative group received 1 epidural steroid injection and could receive other treatments including NSAIDS, analgesics, physical therapy and certain types of braces (abdominal binders and corsets). Patients in the X-Stop group underwent surgery, and received the X- stop implants at one or two levels. the operative levels were confirmed through fluoroscopy. Patients who did not have significant co-morbidities generally returned home the day of surgery. Source of outcome data: Self-report instruments; radiographic analysis at each visit. Length of follow-up: Appeared to be 2 years. Follow-up at 6 weeks, 6 months, 1 year and 2 years.

2 Validity Blinding? No. Appropriate randomization procedures? May not have been appropriate. Used block randomization (blocks of 2) by center. That means, when a patient is randomized to one intervention, the next patient will receive the other intervention. It is possible to choose patients for a particular intervention. Appropriate comparison intervention (placebo or adequate dose of accepted intervention)? No. The intervention was compared to non-operative treatment, which all participants had already failed (this was an eligibility requirement). In addition, there was no standard protocol for non-operative treatment and it is not clear whether treatment was optimized. Treatment/control groups comparable at baseline? Appeared similar on reported characteristics. Other than intervention, was care/follow-up similar in each group? No. Some patients received laminectomy during the follow-up period (6 patients in the X-Stop group and 24 patients in the non-operative group). Adequate compliance with intervention? Not in control group. Sufficient statistical power? Not reported. Intention to treat analysis? No. The 9 control patients who dropped out after randomization were not included. It was not clear whether patients who did not complete the ZCG were included in the analysis the authors did not report sample sizes in their reporting of the main outcomes. The authors did report that patients who had implants removed, withdrew from the study or went on to laminectomy were considered failures from the time of that event forward.. Completeness of follow-up: 9 patients in the non-operative group withdrew before treatment (mostly because they had hoped to be in the X-Stop group). At the 1 year follow-up, 88% of randomized patients in the X-Stop group and 68% of those in the non-operative group completed the ZCQ. At the 2 year follow-up, data were available on 93 X-Stop patients and 81 non-operative patients (93% and 81% of randomized patients, respectively). Industry funding? Yes. Industry funds were received and the two primary authors were the inventors of the X-Stop technology. Conclusions regarding validity of methods: Threats to validity include: - Inappropriate comparison group: X-Stop was compared to non-operative therapy. However, to be eligible for the study, all patients had to have failed 6 months of nonoperative therapy. Thus, the control group consists of patients who are less likely to respond to the intervention. In addition, the conservative treatment received by the control group was not standardized and may not have been optimal. - Lack of blinding, expectations about treatment and subjective outcomes-out: 9 patients dropped out of the control group immediately after randomization the authors mention that this was largely because they had hoped to be randomized to X-Stop. It is likely that other patients who remained in the study also hoped to be randomized to X-Stop and were disappointed with their treatment group. Since the study was blinded and the primary outcomes were self-report, patients expectations could bias outcomes. - ZCQ as primary outcome: The test-retest reliability and internal consistency of the scale has been validated, but not its ability to evaluate clinical improvement.

3 - Incomplete reporting of outcomes and statistics. Many of the outcomes were reported only in figures, exact proportions and p-values were not reported. - Industry funding: The first two authors were inventors of the X-Stop and stood to benefit financially if the device was found to be effective. - There was no clear protocol for when a patient was eligible to receive laminectomy. However, patients who received laminectomy were considered treatment failures. It is possible that patients in the X-Stop group were discouraged from undergoing laminectomy and/or patients in the control group were encouraged to get laminectomy, which could bias outcomes. - Low follow-up rate in the control group, only 68% of patients in the non-operative group completed the ZCQ at 1 year. - Possibly ineffective randomization, using blocks of 2. Results Note on ZCQ: The ZCQ measures three domains: symptoms severity, SS, (7 questions, scored 1-5), physical function. PH, (5 questions, scored 1-4), patient satisfaction, PS (6 questions, scored 1-4, lower is more satisfied). Treatment is considered successful if the patient has an average score of 2.5 on PS, and at least a 0.5 improvement in both SS and PH. Mean pre-treatment ZCQ scores for the SS and PF domains, patients who received treatment X-Stop group Non-operative group n=100 n=91 SS 3.14 3.12 PF 2.48 2.49 Proportion of patients improved at 1 year, according to the ZCQ, completer analysis X-Stop group Non-operative group n=88 n=68 SS 75% 35% PH 75% 30% PS 75% 50% Clinical success 60% 15% Notes: - Exact percentages were not reported. Proportions were estimated from figures - The authors did not specify the criteria for improvement in this analysis. It appears to be the 0.5 point improvement that is part of the overall success measure for the ZCQ. - P-values were not reported. The authors wrote that the X-Stop group had significantly more improvement. - Clinical success=significant improvement in SS and PH dimensions and satisfied with care.

4 Proportion of patients improved at 2 years, according to the ZCQ, completer analysis X-Stop group Non-operative group p-value n=93 n=81 SS 60.2% 18.5% <0.001 PH 57.0% 14.8% <0.001 PS 73.1% 35.9% <0.001 Clinical success 48.4% 4.9% Not reported Mean SF-36 scores at 1 year X-Stop group Non-operative group Physical function 62.2 42.7 Role physical 57.0 31.9 Bodily pain 56.1 36.9 General health 73.0 64.4 Vitality 53.0 47.4 Social function 79.3 67.3 Role emotional 77.1 58.1 Mental health 66.8 60.4 Notes: - No significant pre-treatment differences in any domain - P-values were not reported. The authors wrote that the X-Stop group had significantly better scores at 1 year. Mean radiographic measurements at 1 year (baseline measurements not provided) X-Stop group Non-operative group p-value Spinous process distance (mm) 52.1 51.0 0.336 Anterior disc height (mm) 9.9 9.7 0.776 Posterior disc height (mm) 5.3 5.1 0.626 Treated level angulation (deg) 14.6 16.5 0.099 L1-L5 angulation (deg) 9.9 9.7 0.776 Foraminal height (mm) 23.2 22.5 0.088 Spondylolisthesis (%) 4.1 5.9 0.201 L1-L5 coronal curve (deg) 4.9 5.8 0.267 Note: 2 year radiographic measurements were similar. Thre were no significant between-group differences.

5 Adverse effects X-Stop Non-operative n=100 n=91 Device related 1 4 NA Intraoperative or procedure-related Respiratory distress 1 0 Coronary episode, ischemic 1 0 Pulmonary edema 1 0 Wound dehiscence or swelling 2 NA Hematoma 1 NA Incisional pain 1 NA Leg parathesia 0 2 Heart attack 0 1 Injection intolerance 0 1 1 One each of malpositioned implant, implant dislodgement or migration, spinous process fracture and increased pain at implant level. Authors Conclusions 2004: The results of this prospective study indicate that the X-Stop offers a significant improvement over non-operative therapies at 1 year with a success rate comparable to published reports of decompressive laminectomy, but with considerably lower morbidity. 2005: The X-Stop provides a conservative yet effective treatment for patients suffering from lumbar spinal stenosis. In the continuum of treatment options, the X-Stop offers an attractive alternative to both conservative care and decompressive surgery. Reviewer s Conclusions The study reported significantly better outcomes in the X-Stop group than the control group at 1 and 2-years, according to self-report data. The validity of the study is threatened factors including a lack of blinding, possible preference for X-Stop on the part of patients, an inappropriate and possibly sub-standard comparison intervention, lack of protocol for undergoing laminectomy during the follow-up period, incomplete reporting of statistical findings and an outcome measure (ZCQ) of questionable validity.